Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Pharmaceuticals

Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
71.3 CHF +2.00% Intraday chart for Cosmo Pharmaceuticals N.V. +7.22% +40.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day
Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024 CI
Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2024 and Revenue Guidance for 2025 CI
Transcript : Cosmo Pharmaceuticals N.V., 2023 Earnings Call, Mar 20, 2024
Cosmo Pharmaceuticals' FY23 Profit, Revenue Drops MT
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cosmo Pharmaceuticals Partner Gets Regulatory Approval for Acne Treatment in Australia MT
Berenberg Lifts Price Target on Cosmo Pharmaceuticals, Maintains Buy Recommendation MT
Medtronic Expands Partnership With Cosmo Pharmaceuticals Unit MT
Cosmo Pharmaceuticals, Medtronic to Boost AI Focus in Expanded Partnership MT
Cosmo Pharmaceuticals Redeems EUR175 Million of Bonds due 2023 MT
Global markets live: Nvidia, Chevron, FedEx, Roche, PepsiCo... Our Logo
Cosmo Pharmaceuticals Files Marketing Authorization Application in Europe for Topical Acne Treatment MT
Cosmo Pharmaceuticals Licenses Acne Treatment Winlevi to Hikma in Middle East, North Africa MT
Cosmo Pharmaceuticals Signs Distribution, Licensing Deals with Glenmark for Acne Cream in Europe, South Africa MT
Cosmo Pharmaceuticals N.V. and Glenmark Specialty S.A. Announce the Signing of Distribution and License Agreements for Winlevi® in Europe and South Africa CI
Global markets live: Arm, Amgen, Lloyds, Novo Nordisk, Nestlé... Our Logo
Cosmo Pharmaceuticals Signs License Deal With Adalvo for Rifamycin MT
Cosmo Pharmaceuticals Cancels Dr. Falk Pharma's EU License for Travelers' Diarrhea Drug MT
Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023 CI
Transcript : Cosmo Pharmaceuticals N.V., H1 2023 Earnings Call, Jul 26, 2023
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Cosmo Pharmaceuticals Posts Lower H1 Post-tax Profit; Revenue Rises MT
Cosmo Pharmaceuticals Starts Late-stage Studies of Hair Loss Drug for Men MT
Cosmo Pharmaceuticals N.V. Announces the Beginning of the Phase III Trials in Men for the Treatment of Androgenetic Alopecia CI
Chart Cosmo Pharmaceuticals N.V.
More charts
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
73.29 EUR
Average target price
95.67 EUR
Spread / Average Target
+30.53%
Consensus
  1. Stock
  2. Equities
  3. Stock Cosmo Pharmaceuticals N.V. - Swiss Exchange
  4. News Cosmo Pharmaceuticals N.V.
  5. Switzerland's Cosmo Pharmaceuticals Secures Licensing Deal for Acne Cream in China